Abstract:Chymotrypsin-like cysteine protease, also known as main protease (3CLpro/Mpro) of SARS-CoV-2, is highly conserved among various coronaviruses. Hence, therapeutics targeting the main protease are likely to show broad-spectrum activity. Peptides are a promising avenue for antiviral therapeutics as they are capable of offering a sustainable strategy to combat infectious diseases. In this work, we screened clinically proven antimicrobial peptides against the cysteine protease of SARS-CoV-2 using state-of-the-art cheminformatics methods including docking and dynamics simulation, statistical analysis, and structure-activity relationship studies. From the molecular docking investigation, three peptides were chosen which showed the high binding affinities [DRAMP18152 (∆G = − 56.56 kcal/mol), DRAMP18160 (∆G = − 59.9 kcal/mol), DRAMP20773 (∆G = − 56.2 kcal/mol)] and active interactions with His41 and Cys145 residues. Molecular dynamics simulation was employed over 250 ns on these three peptide-Mpro complexes. The MD simulation results reflect the high inhibitory potential of DRAMP18152, DRAMP18160, and DRAMP20773 against Mpro. These three peptides were synthesized using standard solid phase peptide synthesis. Purity (> 90%) and identity of the peptides were established by liquid chromatography and electrospray ionization-mass spectrometry. FRET-based protease assay was conducted for these three top candidates in which only DRAMP18160 showed the inhibition efficiency with an estimated 50% inhibitory concentrations of 59 μM with low cytotoxicity. These results suggest that pursuing further development of peptide-based inhibitors for antiviral applications may be a fruitful endeavor and yield novel antiviral therapeutics.

De Novo Discovery of a Noncovalent Cell-Penetrating Bicyclic Peptide Inhibitor Targeting SARS-CoV-2 Main Protease

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS‐CoV‐2 Main Protease with Antiviral Activity

Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Bicyclic Peptide-Enhanced Covalent Inhibitor of SARS-CoV-2 3CL Protease

Identification of Covalent Cyclic Peptide Inhibitors Targeting Protein-Protein Interactions Using Phage Display

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease

Highly Efficient Synthesis of Maleimide-braced Peptide Macrocycles and Their Potential Anti-SARS-CoV-2 Mechanisms

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease

Cyclic β2,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease

Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease

Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease

Molecular Modelling, Synthesis, and In-Vitro Assay to Identify Potential Antiviral Peptides Targeting the 3-Chymotrypsin-Like Protease of SARS-CoV-2

Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity

A Potential Molecular Inhibitor of the SARS-COV-2 Main Protease Obtained by Virtual Screening

Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors

Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation

De Novo Design of SARS-CoV-2 Main Protease Inhibitors with Characteristic Binding Modes